Hasnain Ali Shah, Wasim Jafri.
An open study to assess the safety and efficacy of Heprovac-B vaccine 10 mcg-dose for adults
J Pak Med Assoc Feb 2008;58(2):88-90.
The Aga Khan University Hospital, Karachi

Heprovac B is a novel recombinant vaccine There are many vaccines available in Pakistani market but Heprovac B claims to be immunogenic even at 10 meg dose.Aim of the study is to determine whether using 10 meg of Heprovac B vaccine is safe and effective in producing sufficient immunity in Pakistani population. One hundred and twenty five subjects, who fulfilled the Inclusion criteria, were enrolled for the study. Heprovac B was administered in a three-dose regimen given at 0, 1 and 6 months and adverse events were recorded. Immunogenicity was tested by measuring hepatitis B surface antibody one month after each dose received. One month after the 3rd dose 98.7% of the subjects were found to be seroprotected with geometric mean titer of 488.83 mIU/1 after the third dose. Heprovac B, vaccine was well tolerated with minimal reported adverse events. It is safe and 10mcg is immunogenic in producing antibodies in Pakistani population against Hepatitis B virus.

Category: Internal Medicine
Keywords: Hepatitis. Hepatitis B. Vaccine. Vaccination. Hepatitis B Vaccine.

Click here for Full Text Article

This article has been viewed 154 times

Submit your Research Synopsis for Free Expert analysis - Search- Feedback - Drug Index
Post and View Comments on this Article